Skip to main content

Quality Management and 10 CFR 35.41 Procedures

By Troy Zhou, PhD, DABR, DABSNM
• 15 min read

10 CFR 35.41 requires every NRC or Agreement State medical-use licensee to develop, implement, and maintain written procedures that provide high confidence that each administration requiring a written directive reaches the correct patient and is delivered in accordance with that directive — making it the preventive backbone that keeps a nuclear medicine or radiopharmaceutical therapy program out of the medical-event reporting pathway of 10 CFR 35.3045. It is one of the most consequential and most frequently overlooked requirements in a medical radioactive material license.

A written directive tells the clinical team exactly what to administer to a specific patient. But an order, however correct, does not administer itself. Between the authorized user's signature and the dose reaching the patient lies a chain of handling, labeling, identity checks, and verification steps — any of which can fail. 10 CFR 35.41 is the rule that requires a licensee to build a reliable process across that chain, so that the right patient receives the right radionuclide, in the right form, by the right route, at the right dose.

This guide explains what 35.41 requires, how it connects to the written directive (35.40) and to medical event reporting (35.3045), and how to build defensible procedures that survive both an inspection and a bad day. DRPS supports medical-use licensees across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware through radiation safety officer and radioactive material license support services.

Introduction

Nuclear medicine and radiopharmaceutical therapy involve administering unsealed radioactive material to patients. For diagnostic imaging at ordinary activities, an error is usually low-consequence. But for therapeutic administrations — I-131 for thyroid cancer, Lu-177 radioligand therapy, Y-90 radioembolization, and similar — an administration to the wrong patient, or a significant deviation from the prescribed activity, can cause real harm. 8

The regulatory system addresses this in two complementary ways. The written directive (10 CFR 35.40) establishes what is to be administered. The procedures for administrations (10 CFR 35.41) establish the process that ensures the directive is executed correctly. And when the process fails badly enough, the medical event rule (10 CFR 35.3045) defines what must be reported and to whom. 1, 3

Understanding 35.41 as the preventive middle layer — not a paperwork formality, but the operational safeguard that stands between a correct order and a correct administration — is the key to a strong program. For the adjacent requirements, see our guides to written directives in nuclear medicine and medical event reporting under 35.3045.

Topic Explanation

What the rule actually says

Under 10 CFR 35.41(a), a licensee must develop, implement, and maintain written procedures to provide high confidence that: (1) the patient's or human research subject's identity is verified before each administration; and (2) each administration is in accordance with the written directive. Under 35.41(b), the licensee must retain a copy of these procedures for the duration of the license. 1

Two phrases carry the weight. "High confidence" sets a performance standard rather than a checklist — the licensee must be able to show that its procedures reliably achieve the outcome. "In accordance with the written directive" means every parameter that defines the administration — radionuclide, chemical or physical form, activity (dose or dosage), route, and for some uses the treatment site — must be confirmed to match the authorized user's order before the dose is given. 1, 2

A risk-informed, performance-based rule

10 CFR 35.41 is the modern successor to the former Quality Management Program. The earlier approach prescribed detailed steps; the current rule is risk-informed and performance-based. It states the required result and lets each licensee design procedures suited to its own radionuclides, staffing, and workflow, which the NRC then evaluates against the "high confidence" standard during inspection. 2 This flexibility is a benefit and a trap: there is no single approved template, so a thin or generic procedure can technically exist while failing to provide real assurance.

Which administrations are covered

35.41 applies only to administrations that require a written directive under 35.40. These include, among others:

  • Any therapeutic administration of a radiopharmaceutical (for example, I-131 sodium iodide for therapy, Lu-177 and Y-90 therapies). 2
  • Any I-131 sodium iodide dosage above the regulatory threshold, including certain diagnostic uses.
  • Other uses specified in 10 CFR 35.40.

Routine diagnostic imaging dosages that do not require a written directive are outside 35.41, although patient-identification discipline is good practice everywhere. For how the prescribed activity itself is determined and documented, see determination of dosage under 35.63.

Key Technical Principles

The three regulatory pillars

Regulation Role What it establishes
10 CFR 35.40 — Written directive The order Dated, signed authorized-user order: radionuclide, dose/dosage, route, patient, treatment details
10 CFR 35.41 — Procedures for administrations The process (preventive) Written procedures giving high confidence the identity is verified and the administration matches the directive
10 CFR 35.3045 — Medical event report The backstop (reactive) Defines when a deviation becomes a reportable medical event and the notification requirements

The 35.41 procedures are what connect the order to safe execution; 35.3045 is what applies when they fail. A program that writes excellent directives but has weak 35.41 procedures is one handling error away from a medical event. 1, 3

Where 35.41 draws the line into a medical event

The reason 35.41 matters so much is that the deviations it is designed to prevent are exactly those that trigger 10 CFR 35.3045. A medical event generally occurs when the dose delivered differs from the prescribed dose and exceeds defined thresholds. The core dose thresholds are: 3

Medical-event dose threshold (any one) Value
Effective dose equivalent difference ≥ 0.05 Sv (5 rem)
Dose to an organ or tissue ≥ 0.5 Sv (50 rem)
Shallow dose equivalent to the skin ≥ 0.5 Sv (50 rem)

combined with a condition such as a total dose or dosage that differs from the prescribed amount by 20% or more, falls outside the prescribed range, or involves the wrong radionuclide, wrong route, wrong individual, or wrong treatment site. 3

A worked example shows how close the margin can be. Suppose a written directive prescribes a therapeutic dosage of A_presc = 5.55 GBq (150 mCi) of I-131, and the administered activity is A_admin = 7.03 GBq (190 mCi). The fractional difference is:

That 26.7% exceeds the 20% criterion. If the associated organ or effective dose also meets its threshold, this is a reportable medical event. The entire purpose of a 35.41 procedure — confirming the dosage against the directive and measuring it in a calibrated dose calibrator before administration — is to catch exactly this discrepancy before the dose is given. 3

Contrast that with a within-tolerance case: an administered A_admin = 5.83 GBq (157.5 mCi) against the same prescription gives a difference of , well under the 20% criterion and not a medical event. The task of 35.41 is to make the first scenario impossible to deliver unnoticed and the second one documented.

"Verify identity" means at least two identifiers

The identity-verification requirement is best met with the broadly accepted patient-safety standard of at least two independent identifiers (for example, full name plus date of birth) before administration — never the room or location alone. A documented case in the literature describes misadministration of 177Lu-DOTATATE instead of 177Lu-PSMA, underscoring that verifying not only the patient but the specific product against the directive is essential. 9 The two-identifier practice and a final verification "time-out" are the operational heart of a defensible procedure.

Clinical Impact

Robust 35.41 procedures change outcomes in concrete ways:

  • They catch wrong-patient errors. Patients with similar names, back-to-back therapy slots, and shared waiting areas create real confusion risk; a disciplined two-identifier check at the point of administration is the last reliable barrier. 8, 9
  • They catch wrong-product and wrong-dose errors. Verifying the radionuclide, chemical form, activity, and route against the written directive — and confirming the measured activity in a calibrated dose calibrator — intercepts dispensing and labeling mistakes before administration. 8
  • They protect staff and program continuity. A medical event triggers NRC notification, investigation, patient and referring-physician notification, and potential enforcement. Preventing the event is far less costly than reporting it. 3
  • They build a reporting culture. Procedures that make it safe and routine to flag a concern — rather than punishing it — are what surface near-misses before they become events. The published 177Lu case explicitly emphasizes encouraging colleagues to report errors and strengthening safety protocols. 9

The relative complexity of nuclear medicine — booking, dispensing, patient data management, and administration — presents many points where errors can enter, which is precisely why well-established, routinely followed procedures backed by quality assurance are essential. 8

Practical Optimization Tips

A defensible 35.41 procedure typically includes:

  1. Two-identifier patient verification at the point of administration (name plus date of birth or medical record number), documented each time. 9
  2. Directive-to-dose reconciliation: confirm radionuclide, chemical/physical form, activity, route, and treatment site against the signed written directive before administration. 1, 2
  3. Calibrated activity measurement: confirm the dose/dosage in a dose calibrator with current QC before administration; see dose calibrator quality control.
  4. A final time-out: a brief, explicit stop-and-verify step immediately before administration, ideally involving a second qualified individual for therapy.
  5. Defined roles: specify who may perform each verification and who may administer, consistent with supervision requirements.
  6. Deviation handling: a written path for what to do when something does not match — stop, notify the authorized user and RSO, and document — before proceeding.
  7. Record retention: retain the procedures for the duration of the license and keep administration records per 10 CFR Part 35 recordkeeping requirements and 10 CFR 35.2041. 1
  8. Periodic review: review and, where needed, revise procedures, and incorporate them into the program the Radiation Safety Committee oversees.

Common pitfalls

  • A generic, unused template. A procedure that exists on paper but does not match actual workflow provides no real "high confidence."
  • Single-identifier verification. Relying on location or a single name invites wrong-patient error.
  • No independent check for therapy. High-consequence therapeutic administrations warrant a second qualified verifier.
  • Skipping the directive reconciliation. Verifying the patient but not the product against the directive misses wrong-radiopharmaceutical events. 9
  • No deviation pathway. If staff do not know how to stop safely, pressure to proceed wins.

Regulatory Considerations

35.41 procedures must be built, implemented, and maintained consistently with the full medical-use framework, and licensees should align them with NRC guidance and their specific license conditions. Key references:

  • 10 CFR 35.41 — the requirement itself: written procedures giving high confidence of identity verification and directive-conforming administration, retained for the license duration. 1
  • 10 CFR 35.40 — the written directive requirements that 35.41 procedures protect. 2
  • 10 CFR 35.3045 — the medical event definition and reporting obligations that 35.41 aims to prevent triggering, including notification of the NRC Operations Center by telephone no later than the next calendar day, a written report within 15 days, and notification of the referring physician and the patient no later than 24 hours after discovery (unless the referring physician will inform the patient or judges it harmful). 3
  • 10 CFR Part 20 — the underlying Standards for Protection Against Radiation. 7
  • NRC NUREG-1556, Volume 9 — program-specific guidance for medical-use licenses, including expectations for procedures, records, and the radiation safety program. 6

Jurisdiction matters. Medical use of byproduct material is regulated by the NRC or by Agreement States administering equivalent rules. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license and inspect medical use under their own radiation-control regulations, while Washington DC and Delaware are regulated directly by the NRC. An Agreement State's wording may differ in detail, so a facility must build its procedures to the authority that actually issues its license. For the broader licensing context, see radioactive material license support and preparing for an NRC inspection. International guidance such as the IAEA Basic Safety Standards similarly requires measures to minimize the likelihood of unintended or accidental medical exposures and to report incidents. 8, 10

Frequently Asked Questions (FAQs)

What does 10 CFR 35.41 require?

10 CFR 35.41 requires a medical-use licensee to develop, implement, and maintain written procedures that provide high confidence that the identity of the patient or human research subject is verified before each administration requiring a written directive, and that each such administration is given in accordance with the written directive. The licensee must retain a copy of these procedures for the duration of the license.

How is 35.41 different from the written directive in 35.40?

The written directive (10 CFR 35.40) is the authorized user's dated, signed order specifying the radionuclide, dose or dosage, and treatment details for a specific patient. 10 CFR 35.41 is the set of written procedures that ensure that directive is actually carried out correctly — verifying patient identity and confirming the administration matches the directive. The directive is the order; 35.41 is the process that protects it.

Which administrations require written-directive procedures?

Administrations that require a written directive — and therefore 35.41 procedures — include therapeutic and certain diagnostic uses such as any I-131 sodium iodide dosage above the regulatory threshold, therapeutic radiopharmaceuticals, and other uses defined in 10 CFR 35.40. Routine diagnostic imaging dosages that do not require a written directive are not covered by 35.41, though good practice applies patient-identification discipline broadly.

Is 10 CFR 35.41 the old Quality Management Program?

In spirit, yes. The former Quality Management Program rule was replaced by a risk-informed, performance-based framework. Rather than prescribing detailed steps, 35.41 states the required outcome — high confidence that the right patient receives an administration consistent with the written directive — and leaves licensees to design procedures that achieve it, which the NRC evaluates during inspection.

How does 35.41 relate to medical event reporting under 35.3045?

They are two ends of the same safety system. 10 CFR 35.41 procedures are preventive: they aim to stop an administration from going to the wrong patient or deviating from the written directive. 10 CFR 35.3045 is reactive: it defines when such a deviation becomes a reportable medical event. Strong 35.41 procedures reduce the likelihood that a medical event ever occurs.

What should 35.41 procedures include at a minimum?

At a minimum, procedures should verify patient or subject identity using at least two independent identifiers before administration, confirm the radionuclide, chemical form, dose or dosage, and route against the written directive, include a time-out or final verification step, define who may perform each check, and specify how deviations are handled and documented. Records of the procedures are retained per 10 CFR 35.2041.

Key Takeaways

  • 10 CFR 35.41 requires written procedures giving "high confidence" that identity is verified and each written-directive administration matches the directive, retained for the license duration.
  • It is risk-informed and performance-based: it states the required outcome, not a fixed checklist, so a generic template is not enough — the procedure must genuinely fit the workflow.
  • 35.41 sits between the written directive (35.40) and the medical event rule (35.3045) as the preventive safeguard that keeps deviations from occurring.
  • The deviations it prevents are exactly those that trigger a medical event: wrong patient, wrong radionuclide, wrong route, or a dosage differing by 20% or more alongside the dose thresholds.
  • At least two independent identifiers plus a directive-to-dose reconciliation and a final time-out are the operational core of a defensible procedure.
  • Build to the authority that issues your license — NRC or the relevant Agreement State — and retain records per 10 CFR 35.2041.

Conclusion

10 CFR 35.41 is easy to underestimate because it produces no image and treats no disease. But it is the quiet process safeguard that determines whether a correct written directive becomes a correct administration. In a field where a single misidentified patient or mislabeled syringe can cause real harm and a reportable medical event, the written procedures required by 35.41 are the last reliable barrier before the dose reaches the patient.

The strongest programs treat 35.41 not as a compliance artifact but as a living process: two-identifier verification, directive reconciliation against a calibrated dose measurement, a genuine time-out, clear roles, a safe way to stop when something does not match, and a culture that rewards flagging concerns. Built that way, 35.41 procedures do double duty — they protect patients and they keep the program out of the medical-event reporting pathway.

How DRPS Can Help

Diagnostic Radiation Physics Services helps medical-use licensees turn regulatory requirements into practical, defensible workflows. For 35.41 and the surrounding framework this may include drafting and reviewing written-directive procedures, patient-identification and time-out protocols, dose-verification practices, deviation-handling pathways, and recordkeeping, all aligned with NRC or Agreement State requirements. These pair naturally with radiation safety officer support, radioactive material license support, and medical physicist consulting.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

Related Resources

References

  1. U.S. Nuclear Regulatory Commission. 10 CFR 35.41: Procedures for administrations requiring a written directive. ecfr.gov
  2. U.S. Nuclear Regulatory Commission. 10 CFR 35.40: Written directives. ecfr.gov
  3. U.S. Nuclear Regulatory Commission. 10 CFR 35.3045: Report and notification of a medical event. ecfr.gov
  4. U.S. Nuclear Regulatory Commission. 10 CFR 35.2: Definitions (medical event). ecfr.gov
  5. U.S. Nuclear Regulatory Commission. 10 CFR 35.2041: Records for procedures for administrations requiring a written directive. ecfr.gov
  6. U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Medical Use Licenses. nrc.gov
  7. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
  8. Marengo M, Martin CJ, Rubow S, Sera T, Amador Z, Torres L. Radiation safety and accidental radiation exposures in nuclear medicine. Semin Nucl Med. 2022;52(2):94-113. doi:10.1053/j.semnuclmed.2021.11.006. PubMed
  9. Samadi MH, Sahafi P, Khezri S, Fazeli Z, Aghaee A. Misadministration of 177Lu-DOTATATE instead of 177Lu-PSMA in a patient with prostate cancer: clinical implications and management. Clin Nucl Med. 2025;50(11):e678-e680. doi:10.1097/RLU.0000000000005711. PubMed
  10. International Atomic Energy Agency. Radiation Protection and Safety of Radiation Sources: International Basic Safety Standards (GSR Part 3). 2014. iaea.org